Rojas-Rivera JE, et al. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J 2019; 12:629−638. doi: 10.1093/ckj/sfz127

• PubMed
Rojas-Rivera JE, Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal. Clin Kidney J 2019; 12:629−638. doi: 10.1093/ckj/sfz127)| false
• Search Google Scholar
• Export Citation

Singh L, et al. Understanding podocytopathy and its relevance to clinical nephrology. Indian J Nephrol 2015; 25:1−7. doi: 10.4103/0971-4065.134531

• PubMed
Singh L, Understanding podocytopathy and its relevance to clinical nephrology. Indian J Nephrol 2015; 25:1−7. doi: 10.4103/0971-4065.134531)| false
• Search Google Scholar
• Export Citation

Ferreira F, Nunes AT. New treatments in membranous glomerulopathy—from the pitfalls of rituximab to a new era of biological treatments. Port J Nephrol Amp Hypertens 2020; 34:160−164. http://doi.org/10.32932/pjnh.2020.10.087

• PubMed
Ferreira F, Nunes AT. New treatments in membranous glomerulopathy—from the pitfalls of rituximab to a new era of biological treatments. Port J Nephrol Amp Hypertens 2020; 34:160−164. http://doi.org/10.32932/pjnh.2020.10.087)| false
• Search Google Scholar
• Export Citation

Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1617−1630. doi: 10.1681/ASN.2012010058

• PubMed
Waldman M, Austin HA 3rd. Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1617−1630. doi: 10.1681/ASN.2012010058)| false
• Search Google Scholar
• Export Citation

Salvadori M, Tsalouchos A. Editor’s pick: New aspects of pathogenesis and treatment of membranous glomerulopathy after the MENTOR study. EMJ Nephrol 2020; 8:46−53. https://www.emjreviews.com/nephrology/article/editors-pick-new-aspects-of-pathogenesis-and-treatment-of-membranous-glomerulopathy-after-the-mentor-study/

• PubMed
Salvadori M, Tsalouchos A. Editor’s pick: New aspects of pathogenesis and treatment of membranous glomerulopathy after the MENTOR study. EMJ Nephrol 2020; 8:46−53. https://www.emjreviews.com/nephrology/article/editors-pick-new-aspects-of-pathogenesis-and-treatment-of-membranous-glomerulopathy-after-the-mentor-study/)| false
• Search Google Scholar
• Export Citation

Fervenza FC, et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427

• PubMed
Fervenza FC, Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 2019; 381:36−46. doi: 10.1056/NEJMoa1814427)| false
• Search Google Scholar
• Export Citation

Delbarba E, et al. Rituximab vs. cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. American Society of Nephrology, Kidney Week. October 22, 2020; PO2638. Accessed December 21, 2020. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3470922

• PubMed
Delbarba E, Rituximab vs. cyclophosphamide in the treatment of membranous nephropathy: The RI-CYCLO trial. American Society of Nephrology, Kidney Week. October 22, 2020; PO2638. Accessed December 21, 2020. https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3470922)| false
• Search Google Scholar
• Export Citation

Fernández-Juárez G, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [Published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.kidney-international.org/article/S0085-2538(20)31251-5/fulltext

• PubMed
Fernández-Juárez G, The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int [Published online ahead of print November 7, 2020]. doi: 10.1016/j.kint.2020.10.014; https://www.kidney-international.org/article/S0085-2538(20)31251-5/fulltext)| false
• Search Google Scholar
• Export Citation

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Rituximab plus cyclosporine in idiopathic membranous nephropathy. ClinicalTrials.gov: NCT00977977. Accessed December 20, 2020. https://clinicaltrials.gov/ct2/show/NCT00977977

• PubMed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Rituximab plus cyclosporine in idiopathic membranous nephropathy. ClinicalTrials.gov: NCT00977977. Accessed December 20, 2020. https://clinicaltrials.gov/ct2/show/NCT00977977)| false
• Search Google Scholar
• Export Citation

Klomjit N, et al. Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: A report of 3 cases. Am J Kidney Dis 2020; 76:883−888. doi: 10.1053/j.ajkd.2020.02.444

• PubMed
Klomjit N, Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: A report of 3 cases. Am J Kidney Dis 2020; 76:883−888. doi: 10.1053/j.ajkd.2020.02.444)| false
• Search Google Scholar
• Export Citation

Sethi S, et al. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 2020; 5:1515−1518. doi: 10.1016/j.ekir.2020.06.030

• PubMed
Sethi S, Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep 2020; 5:1515−1518. doi: 10.1016/j.ekir.2020.06.030)| false
• Search Google Scholar
• Export Citation

Marcus R, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377:1331−1344. doi: 10.1056/NEJMoa1614598

• PubMed
Marcus R, Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377:1331−1344. doi: 10.1056/NEJMoa1614598)| false
• Search Google Scholar
• Export Citation

Hoffmann-La Roche. A phase III randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy. ClinicalTrials.gov: NCT04629248. Accessed December 29, 2020. https://clinicaltrials.gov/ct2/show/NCT04629248

• PubMed
Hoffmann-La Roche. A phase III randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy. ClinicalTrials.gov: NCT04629248. Accessed December 29, 2020. https://clinicaltrials.gov/ct2/show/NCT04629248)| false
• Search Google Scholar
• Export Citation